MannKind Corporation (Nasdaq:MNKD) TASE:MNKD) and One Drop today
announced that they have signed a memorandum of understanding to
enter into a collaborative agreement that would extend One Drop’s
subscription service and digital health platform – which currently
provides unlimited blood glucose testing supplies and 24/7 live
in-app support from diabetes experts – by adding Afrezza as a
rapid-acting insulin offering.
The planned collaboration will include three consumer-focused
areas:
- Access, Cost Savings and Convenience
initiatives, intended to simplify the complexity of starting and
staying on mealtime insulin.
- Customized Coaching and Engagement designed to
help people on Afrezza achieve the American Diabetes Association
(ADA) recommendation of an A1C goal of less than 7%.
- Design innovation around packaging and
exploration of a reusable Afrezza Inhaler with integrated Bluetooth
technology.
“Against a backdrop of soaring insulin costs, this proposed
collaboration is an essential step in the right direction,” said
Jeff Dachis, CEO and Founder of One Step. “One Drop began with the
goal of bringing affordable, accessible diabetes care to everyone
living with diabetes worldwide. Through this partnership with
MannKind, we will continue to work tirelessly to empower everyone
with diabetes to achieve better health outcomes through the use of
modern delivery methods that reduce the burden of diabetes
management and increase engagement in self-care.”
“The complexity and conflicting incentives of the United States
healthcare system are not aligned to help people with diabetes on
insulin achieve optimal outcomes, as we see that almost seven out
of ten people on mealtime insulin are not at the ADA goal of <7%
A1C,” said Michael Castagna, Chief Commercial Officer of MannKind
Corporation. “Even though injectable insulins have been
available for decades, 20% of users regularly skip
injections. We intend to empower people with diabetes to take
charge of their health by trying something different.”
“We believe that diabetes care as a fully integrated digital
service is the only way that we are going to bend the cost curve
for payers and providers, while at the same time delivering
evidence-based health outcomes that can scale,” continued Dachis.
“Working with an innovator like MannKind, with a clinically
effective, non-invasive inhaled mealtime insulin product, offers up
an exciting opportunity to further our mission of relentlessly
improving the lives of everyone with diabetes and a
smartphone.”
One Drop recently presented findings from a retrospective study
demonstrating that One Drop | Mobile app users report a substantial
improvement in blood glucose levels, reducing A1c by 1.0 percentage
point (8.2% to 7.2%) after only 2 to 12 months of using One Drop |
Mobile.[1]
One Drop has also shared preliminary data collected from people
with diabetes using One Drop | Mobile and One Drop | Experts for
just four consecutive weeks, showing that One Drop users:
• reduced average blood glucose by 27 mg/dL;
• reduced average blood glucose from 185 mg/dL (A1c
8.1%) to 158 (A1c 7.1%);
• reduced average percentage of high blood glucose
readings from 19% to 4%;
• nearly doubled the percentage of in-range blood
glucose readings; and
• consistently tracked food and blood glucose over
time.[2]
In the next few months, One Drop will present the complete
results of several clinical studies conducted over the past year.
Altogether, One Drop | Mobile users have contributed more than 280
million primary health data points, which One Drop analyzes to
deliver powerful insights that drive improved health outcomes for
people with diabetes, as well as immediate proven cost-savings for
both people with diabetes and their care providers.
“Our approach is to advance traditional therapies by delivering
better access to scalable care, better education, more convenience,
lower costs, and an improved user experience,” said Dachis.
“Ultimately, we must deliver results. There is too much at stake
for business as usual.”
ABOUT MANNKIND
CORPORATIONMannKind Corporation (NASDAQ:MNKD) (TASE:MNKD)
focuses on the discovery, development and commercialization of
therapeutic products for patients with diseases such as
diabetes. MannKind maintains a website
at www.mannkindcorp.com to which MannKind regularly posts
copies of its press releases as well as additional information
about MannKind. Interested persons can subscribe on the MannKind
website to e-mail alerts that are sent automatically when MannKind
issues press releases, files its reports with the Securities and
Exchange Commission or posts certain other information to the
website.
_______________
1 Osborn, C. Y., et al. (2017, March). One Drop App Users
Report Improved Glycemic Control. Poster session presented at the
Society of Behavioral Medicine 38th Scientific Sessions, San Diego,
CA.
2 Osborn, C. Y., et al. (2017, March). The One Drop |
Mobile App and Experts Program is Evidence-based and Improves Blood
Glucose. Poster session presented at the Society of Behavioral
Medicine 38th Scientific Sessions, San Diego, CA.
3 The American Diabetes Association recognizes this
education service as meeting the National Standards for Diabetes
Self-Management Education and Support.
About One Drop
One Drop (Informed Data Systems Inc.) is a digital health
company harnessing the power of mobile computing and data science
to transform the lives of everyone with diabetes.
One Drop's offerings include the first-ever monthly subscription
service to provide clinically effective, affordable, accessible
diabetes care. For less than the cost of a monthly co-pay, One Drop
subscribers receive:
- One Drop | Chrome with Unlimited Testing
Supplies: One Drop | Chrome not only meets the highest
standards of clinical accuracy, but also wirelessly transmits blood
glucose data directly to the cloud via the One Drop | Mobile app
for iOS and Android. Unlimited blood glucose test strips are
delivered on-demand directly to the doors of One Drop subscribers —
no prescriptions, no insurance, no appointments, and no
hassles.
- One Drop | Experts for Anytime Care: One Drop
| Experts moves diabetes education out of the clinic and into the
lives of people with diabetes. Each One Drop | Premium subscriber
has his/her own “Expert” (Certified Diabetes Educator) available
24/7 for guidance, support, and anytime care. Experts deliver
personalized digital therapeutics programs, including
ADA-recognized diabetes education[3], to help people with diabetes
define and achieve their health management goals. Subscribers can
communicate with their Experts anytime via in-app chat; all data
recorded in the app is available to Experts in real-time, allowing
them to provide relevant behavioral guidance in the moments when
subscribers need it most. No appointments necessary.
- One Drop | Mobile: One Drop | Mobile is an
award-winning, cloud-based diabetes management solution delivered
entirely via mobile app on iOS and Android. One Drop | Mobile
provides real-time and historical blood glucose data and analytics
to subscribers and their healthcare providers, allowing both to see
relationships between specific health behaviors and health
outcomes. One Drop | Mobile also includes a fully-featured Apple
WatchOS app for logging and analyzing diabetes data on the go. One
Drop | Mobile is the only diabetes management platform that offers
comprehensive self-care, peer-support, and expert support all in
one place.
One Drop also offers an enterprise solution, One Drop |
Professional, for insurers, health care provider networks,
and self-insured employers to dramatically lower the cost of caring
for people with diabetes. The One Drop | Mobile solution is
available for free worldwide. One Drop | Chrome is sold exclusively
by One Drop (iOS, Android, and http://onedrop.today/), Amazon
(http://www.amazon.com), and Apple (http://store.apple.com). One
Drop's consumer subscription service is available for purchase
in-app (iOS and Android) and at http://onedrop.today. For more
information, contact just@onedrop.today.
MannKind Contact:
Rose Alinaya
SVP, Finance
661-775-5300
ralinaya@mannkindcorp.com
One Drop Contact
Rachel M. Sanchez
917-342-2892
rachel@onedrop.today
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Jun 2024 to Jul 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Jul 2023 to Jul 2024